Designing clinical trials to support population PK/PD modeling requires careful choices of sampling times, number of subjects, dose groups and other trial features to
ensure precise parameter estimation - with low relative standard errors [1].
Designing clinical trials to support population PK/PD modeling requires careful choices of sampling times, number of subjects, dose groups and other trial features to
ensure precise parameter estimation - with low relative standard errors [1].
Biosimilar development is crucial to making lifesaving treatments more affordable and accessible to patients—and researchers are under increasing pressure to reduce cost and time without compromising scientific rigor
In this video we'll be talking about Introduction to Reprise Licensing.
In this video we'll be talking about Injectables Intramuscular.
In this video we'll be talking about Injectables Subcutaneous.
In this video we'll be talking about AssessmentsPlus.
In this video we'll be talking about P-PSD.
In this video we'll be talking about Orchestrator.
In this video we'll be talking about GPX ACATPlus.
Triple-negative breast cancer (TNBC) is highly aggressive with limited treatment options, and resistance to doxorubicin (DOX) further compromises outcomes.
In this video we'll be talking about Introduction to ACAT.
In this video we'll be talking about PDPlus Module.
In this video we'll be talking about IVIVCPlus Module.
In this video we'll be talking about PKPlus Module.
In this video we'll be talking about DDI Module.
In this video we'll be talking about Metabolism and Transport Module.
In this video we'll be talking about PBPKPlus Module.
In this video we'll be talking about recreating a GPX project in legacy GastroPlus.
In this video we'll be talking about lab book.
In this video we'll be talking about reporting outputs.